BioNTech

BioNTech 2026大重构：关厂减支、创始人退场与15项三期临床的终极考验

BioNTech双线告捷：专利战裁定胜利，ADC肿瘤药步入FDA审批通道

BioNTech Prepares for a Pivotal Year: Seven Late-Stage Trials, Cost Cuts, and a Change at the Helm

BioNTech”自断经脉”求生：五厂甩卖与创始人”出走”背后的背水一战

angelina -

BioNTech’s Patent Win and Lancet Validation Contrast With Analyst Downgrades

angelina -

BioNTech Charts a New Course: Factory Fire Sale and Founder Exit Amid a Cancer Bet

kashif hafeez -

BioNTech”后新冠时代”三线突围：卖厂缩编、创始人交棒、十亿美元回购护盘

angelina -

BioNTech Races Toward an Oncology Pivot as Factory Sales and a Prostate Cancer Trial Drive Sentiment

kashif hafeez -

BioNTech战略转向：关厂变卖厂，五处基地迎来买家谈判

kashif hafeez -

BioNTech剥离德国根系：168亿欧元现金弹药与七项临床数据决定下半年走向

angelina -

BioNTech’s Balancing Act: A Founder Exodus Meets a Make-or-Break Oncology Pipeline

Brett Shapiro -

BioNTech的转折之战：十亿美元回购托底，肿瘤药FDA申请进入读秒

Brett Shapiro -

BioNTech Faces Twin Uncertainties: Who Will Lead and Who Will Own the Oncology Pipeline?

BioNTech六月末关键战役：分拆、收购与ADC临床数据三重共振

BioNTech Enters a Second Half Defined by Seven Readouts and a Leadership Puzzle

angelina -
1...456...15Page 5 of 15